Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Limited sampling model for vinblastine pharmacokinetics.

M J Ratain¹, N J Vogelzang

¹Lynn Sage Clinical Pharmacology Laboratory for Cancer Research, Department of Medicine, University of Chicago Pritzker School of Medicine, IL.

Cancer Treatment Reports

|October 1, 1987

Summary

A simplified model estimates vinblastine

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

BMC cancer·2021

Same author

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Cancer treatment and research communications·2019

Area of Science:

Pharmacokinetics
Pharmacodynamics
Oncology

Background:

Vinblastine is an anticancer drug requiring pharmacokinetic monitoring.
Accurate assessment of area under the concentration-time curve (AUC) is crucial for understanding drug efficacy and toxicity.
Traditional pharmacokinetic analysis involves frequent blood sampling, which can be burdensome.

Purpose of the Study:

To develop and validate a limited sampling model for estimating the total area under the concentration-time curve (AUC) of vinblastine.
To enable simplified pharmacokinetic assessments in clinical settings.
To facilitate large-scale pharmacodynamic studies of vinblastine and other anticancer agents.

Main Methods:

A pharmacokinetic model was developed using multiple linear regression.
Serum vinblastine concentrations were measured at 16 timepoints in 30 patients.
The model utilized two timepoints (10 and 36 hours) to predict total AUC.
The model was trained on 15 patients and validated on an independent set of 15 patients.

Main Results:

A validated limited sampling model was established: AUC = 38.0 C10 + 73.8 C36 - 12.9.
The model demonstrated high correlation in both training (r = 0.99) and validation (r = 0.94) datasets.
The mean predictive error for AUC estimation was 13%.

Conclusions:

A two-timepoint limited sampling model accurately estimates vinblastine's total AUC.
This simplified approach reduces the need for intensive pharmacokinetic sampling.
The model can support large-scale pharmacodynamic studies, correlating AUC with clinical outcomes like toxicity and response.

Related Experiment Videos